Digmbio LOGO

DIGMBIO IN THE NEWS

Digmbio in the News 목록
DigmBio has achieved the IND approval of its selective PARP1 inhibitor by the Korea Food and Drug Administration (MFDS). . READ MORE Pharma Focus Asia March 26, 2024
DigmBio announced its selective PARP1 inhibitor has been approved by Korea Food and Drug Administration (MFDS) for IND application. . READ MORE PR News Wire March 26, 2024
DigmBio's Parkinson's disease project was recognized in 2023 as a recipient of a grant from the Korea Drug Development Fund. The Appointment of the National New Drug Development Projects in 2023 The Korea Drug Development Fund selected DigmBio's Parkinson's disease project as a recipient of a grant to further its efforts in lead optimization. Jung-Ho Kim, DigmBio's CSO, leads the project as the project manager. Click here to read Korean version READ MORE Korea Drug Development Fund April 27, 2023
DigmBio unveiled its AACR poster presentation “DM5167, a novel selective PARP1 inhibitor that effectively reduces the growth of triple-negative breast cancers . READ MORE AACR Journals April 1, 2023
Digmbio’s Alzheimer’s disease project received a grant from Korea Dementia Research Center sponsored by the Ministry of Science & ICT and the Ministry of Health & Welfare. DigmBio, led by CEO Kim Jeong-min, has been selected for the prestigious '2021 Dementia Overcoming Research and Development Project' backed by the Ministry of Science and ICT and the Ministry of Health and Welfare. Their research topic focuses on developing a new non-clinical candidate for Alzheimer's treatment targeting TASR GPCR. Their preliminary cand . . . READ MORE The Yakup May 11, 2021

검색